Cerca
image du produit
American Heart Journal

Abbonarsi

Sirolimus-eluting iron bioresorbable scaffold versus cobalt-chromium everolimus-eluting stents in patients with coronary artery disease: Rationale and design of the IRONMAN-II trial - 16/08/24

Doi : 10.1016/j.ahj.2024.05.019 
Lei Song, MD a, b, c, Changdong Guan, MSc c, Mengyue Yu, MD a, d, Zhongwei Sun, MSc c, Guosheng Fu, MD e, Yong He, MD f, Shaobin Jia, MD g, Jiyan Chen, MD h, Feng Qi, MD d, Jie Bai, MD d, Wei li, MD i, Junbo Ge, MD j, Yaling Han, MD k, Runlin Gao, MD a, d, ⁎
a Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China 
b National Clinical Research Center for Cardiovascular Diseases, Beijing, China 
c Catheterization Laboratories, Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China 
d Department of Cardiology, Fuwai Yunan hospital, Chinese Academy of Medical Sciences, Kunming, China 
e Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China 
f Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China 
g Department of Cardiology, General Hospital of Ningxia Medical University, Yinchuan, China 
h Department of Cardiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China 
i Medical Research and Biometrics Center, National Center for Cardiovascular Diseases, Beijing, China 
j Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Disease, Shanghai, China 
k Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China 

⁎Reprint requests: Runlin Gao, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, A 167 Beilishi Road, Xicheng District, Beijing 100037, China.Department of CardiologyFuwai HospitalNational Center for Cardiovascular DiseasesChinese Academy of Medical Sciences and Peking Union Medical CollegeA 167 Beilishi Road, Xicheng DistrictBeijing100037China

Abstract

Background

The previous first-in-human study established the preliminary safety and effectiveness of the novel thin-strut iron bioresorbable scaffold (IBS). The current study aims to directly compare the imaging and physiological efficacy, and clinical outcomes of IBS with contemporary metallic drug-eluting stents (DES).

Methods

A total of 518 patients were randomly allocated to treatment with IBS (257 patients) or metallic DES (261 patients) from 36 centers in China. The study is powered to test noninferiority of the IBS compared with the metallic everolimus-eluting stent in terms of the primary endpoint of in-segment late lumen loss at 2 years, and major secondary endpoints including 2-year quantitative flow ratio and cross-sectional mean flow area measured by optical coherence tomography (OCT) (limited to the OCT subgroup, 25 patients in each group).

Conclusion

This will be the first powered randomized trial investigating the safety and efficacy of the novel thin-strut IBS compared to a contemporary metallic DES. The findings will provide valuable evidence for future research of this kind and the application of metallic bioresorbable scaffolds.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2024  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

    •

  • Contenuto

    •

Vol 275

P. 53-61 - settembre 2024 Ritorno al numero
Articolo precedente Articolo precedente
  • Design and rationale of the cardiometabolic health program linked with community health workers and mobile health telemonitoring to reduce health disparities (LINKED-HEARTS) program
  • Yvonne Commodore-Mensah, Yuling Chen, Oluwabunmi Ogungbe, Xiaoyue Liu, Faith E. Metlock, Kathryn A. Carson, Justin B. Echouffo-Tcheugui, Chidinma Ibe, Deidra Crews, Lisa A. Cooper, Cheryl Dennison Himmelfarb
| Articolo seguente Articolo seguente
  • Intramuscular versus enteral penicillin prophylaxis to prevent progression of rheumatic heart disease: Study protocol for a noninferiority randomized trial (the GOALIE trial)
  • Joselyn Rwebembera, Emma Ndagire, Natalie Carvalho, Allison R. Webel, Craig Sable, Emmy Okello, Rachel Sarnacki, Alison M. Spaziani, Atukunda Mucunguzi, Daniel Engelman, Anneke Grobler, Andrew Steer, Andrea Beaton

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account

Aide & support

Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.

Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.